[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracoabdominal-aortic-aneurysms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracoabdominal-aortic-aneurysms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100570722","thoracoabdominal-artery-stent-graft-system-exploratory-study-100570722",false,"NCT06710938","Thoracoabdominal Artery Stent Graft System Exploratory Study","Exploratory Study of Thoracoabdominal Artery Stent Graft System in the Treatment of Thoracoabdominal Aortic Aneurysms","Inclusion Criteria:\n\n1. Age: 18 to 80 years old;\n2. Patients diagnosed with a Thoracoabdominal aortic aneurysm (based on the modified Crawford classification and European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms), and should meet at least ONE of the following conditions:\n\n   1. Maximum diameter of TAAA is \\>50 mm;\n   2. TAAA diameter increases by more than 5 mm in the past 6 months or by more than 10 mm in the past 1 year;\n   3. Definite symptoms associated with TAAA, such as abdominal pain and back pain.\n3. Anatomical Criteria\n\n   1. Proximal landing zone (aorta or implanted graft): the diameter ranges from 17 to 36 mm, and length should be ≥25 mm;\n   2. Distal landing zone (aorta or implanted graft): If distal landing zone is in iliac artery, distal landing zone diameter ranges from 7 to 25 mm, and length should be ≥15 mm; If the distal landing zone is in the abdominal aorta, distal landing zone diameter ranges from 12 to 36 mm, and length should be ≥20 mm.\n   3. Visceral branch landing zone: the diameter ranges from 6 to 13 mm, and the length should be ≥15 mm;\n   4. Renal artery landing zone: the diameter ranges from 4.5 to 9 mm, and the length should be ≥15 mm;\n   5. Appropriate iliac, femoral, and upper limb arterial access.\n4. Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol;\n5. Patients do not want to or cannot wait for the approved alternative\n\nExclusion Criteria:\n\nExclusion Criteria (not eligible if any of the criteria is met):\n\n1. Patients with ruptured thoracoabdominal aortic aneurysms in unstable hemodynamic condition;\n2. Patients with thoracoabdominal aortic dissection;\n3. Patients with infected or mycotic thoracoabdominal aortic aneurysms;\n4. Patients with systemic or local infections that may increase the risk of endovascular graft infection;\n5. Patients with occluded superior mesenteric artery, celiac trunk artery, or renal artery;\n6. Patients requiring simultaneous coverage or embolization of bilateral internal iliac arteries;\n7. Patients with severe stenosis, calcification or mural thrombus at stent-graft landing zone, and this situation leads to difficulty in adhering the covered stent or affecting the patency of the stent;\n8. Patients with a history of acute coronary syndrome within the recent 6 months; Acute coronary syndrome refers to acute cardiac ischemic syndrome caused by rupture or erosion of unstable atherosclerotic plaques in the coronary artery and fresh thrombosis, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris.\n9. Patients with transient ischemic attack (TIA) or ischemic\u002Fhemorrhagic stroke within the recent 3 months;\n10. Patients with abnormal liver and kidney function before operation \\[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 5 times the upper limit of normal value; Serum creatinine (Cr) \\>150umol\u002FL\\];\n11. Patients with severe pulmonary insufficiency who cannot tolerate general anesthesia;","ALL","18 Years","80 Years",{"count":20,"type":21},11,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).",[27],"Thoracoabdominal Aortic Aneurysms",[27,29,30,31],"G-branch Stent Graft","Lifetech Scientific","Thoracoabdominal Artery Stent Graft System","RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-26","ACTUAL",{"date":38,"type":36},"2025-07-24",{"date":40,"type":21},"2032-06-30",{"name":42,"class":43},"Lifetech Scientific (Shenzhen) Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100443483","safety-and-efficacy-of-a-multi-branched-thoracoabdominal-stent-graft-system-for-thoracoabdominal-aortic-aneurysm-100443483","NCT05054985","Safety and Efficacy of a Multi-branched Thoracoabdominal Stent Graft System for Thoracoabdominal Aortic Aneurysm.","Guo's Renovisceral Artery Reconstruction-1: a Prospective, Multicenter, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of a Multi-branched Stent Graft System for Thoracoabdominal Aortic Aneurysm (GUARANTEE Study)","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 80 years old;\n2. Diagnosed as thoracoabdominal aortic aneurysm (based on modified Crawford classification and 2019 European Guidelines for the Treatment of Aortic aneurysm) and should meet at least one of the following conditions;\n\n   1. Maximum diameter of thoracoabdominal aortic aneurysm\\>50mm;\n   2. The diameter has increased by more than 5mm in recent 6 months or the by more than 10mm in recent 1 year;\n3. anatomical criteria\n\n   1. The proximal anchoring region (aorta or implanted graft) was 17\\~36 mm in diameter and ≥25 mm in length;\n   2. Distal anchoring region (aorta or implanted graft): If the distal anchoring region is in the iliac artery, the anchoring region has a diameter range of 7\\~25 mm and a length of ≥15 mm; If the distal anchoring area is in the abdominal aorta, the diameter of the anchoring area ranges from 12\\~36mm and the length≥ 20mm;\n   3. The diameter of the vessel anchoring area of the visceral branch ranges from 6\\~13 mm and the length ≥15 mm;\n   4. The diameter of renal artery anchoring area ranges from 4.5\\~9mm, and the length ≥15 mm;\n   5. Appropriate iliac, femoral and upper limb artery access;\n4. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent, and are willing to complete the follow-up according to the requirements of the protocol;\n\nExclusion Criteria:\n\n1. Hemodynamically unstable patients with ruptured thoracoabdominal aortic aneurysms;\n2. Thoracoabdominal aortic dissection;\n3. Mycotic or infectious thoracoabdominal aortic aneurysm;\n4. Patients whose systemic or local infection may increase the risk of intravascular graft infection;\n5. Superior mesenteric, celiac, or renal artery occlusion;\n6. Requiring simultaneous coverage and embolization of bilateral internal iliac arteries;\n7. Severe stenosis, calcification, or mural thrombus in the anchoring area of the stent tend to have difficulty in attachment of the stent-graft or affect the patency of the stent;\n8. A history of acute coronary syndrome within 6 months; Acute coronary syndrome is defined as an acute ischemic syndrome of the heart resulting from the rupture or erosion of unstable intracoronary atherosclerotic plaques followed by fresh thrombosis, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina pectoris.\n9. Transient ischemic attack (TIA) or ischemic\u002Fhaemorrhagic stroke within 3 months;\n10. Preoperative liver renal function abnormalities (ALT or AST ≥ 5 times the upper limit of normal value), or serum creatinine ≥ 150 μmol\u002FL;\n11. Severe pulmonary insufficiency who cannot tolerate general anaesthesia;\n12. Severe coagulation dysfunction;\n13. Undergone major surgical or interventionic surgery within 30 days before surgery;\n14. A history of allergy to contrast agents, anticoagulants, antiplatelet drugs, stents, and conveyor materials (nitinol, polyester, PTFE, nylon);\n15. Connective tissue diseases such as systemic lupus erythematosus, Marfan's syndrome, Adam's syndrome, or Behcet's disease;\n16. takayasu arteritis;\n17. Serious vital organ dysfunction or other serious disease;\n18. Planning pregnancy, pregnancy, or breastfeeding;\n19. Patients who participated in other clinical trials and was not discontinued or withdrawn within the first 3 months of the screening period of this trial.\n20. Life expectancy less than 1 year;\n21. Patients who, in the judgment of the investigator, are not eligible for endotherapy.",{"count":53,"type":21},73,[24],"Evaluation of the safety and efficacy of a multi-branched thoracoabdominal stent graft system for thoracoabdominal aortic aneurysm.",[27],[58,59,60],"Guo's Visceral Arteries Reconstruction","Multi-branched Thoracoabdominal Stent Graft System","Thoracoabdominal Aortic Aneurysm","2025-06-17",{"date":63,"type":36},"2025-06-22",{"date":65,"type":36},"2021-11-12",{"date":67,"type":21},"2028-12-31",{"name":42,"class":43}]